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Improved Outcomes, Uncertain Future*David J. Goldberg, MDS ince its introduction in 1971, the Fontan opera-tion has become a mainstay of the palliativestrategy for infants born with the heteroge-
neous collection of congenital heart defects charac-
terized by a functional single ventricle (1,2). Over
the years, since the initial publications describing
this procedure, a number of technical modiﬁcations
to the surgical strategy have resulted in improved
outcomes, allowing generations of children to survive
into their adult years (3–5). In the current era, periop-
erative mortality is low, but there remain questions
regarding the long-term viability of this man-made
circulation (6).SEE PAGE 1700In this issue of the Journal, Pundi et al. (7) report
the outcomes of the Fontan operation at the Mayo
Clinic over a 40-year period, covering almost the
entirety of the history of this operation. This impor-
tant work demonstrates the success of the Fontan
operation as part of the palliative strategy but also
points to some of the challenges associated with the
physiology created by the operation.
Perhaps most striking, but not surprising, is the
improvement in short- and long-term outcomes in
more recent eras. In this paper, the authors describe
a late survival of 95% at 10 years for the cohort that
underwent a Fontan operation after 2001. Survival in
the initial era (1973 to 1990) was 69%, and survival in
the middle era (1991 to 2000) was 89%. Although it is*Editorials published in the Journal of the American College of Cardiology
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disclose.certainly too soon to predict the 20- and 30-year
survival rates for the most recent cohort, the 10-year
data provide a reason for optimism and suggest that
the myriad of small advances in surgical approach
and post-operative management over the last 40
years have, in sum, led to important overall im-
provements in outcomes.
Over time, congenital heart surgeons have moved
away from the atriopulmonary connection, instead
generally favoring an intra-atrial lateral tunnel or an
extracardiac conduit. In the current paper, the
extracardiac conduit appeared to have the lowest
mortality, although it may be that the lateral tunnel
suffered in this comparison due to its use in an earlier
era. This paper also documented the increased mor-
tality associated with performing the Fontan opera-
tion in “high-risk” patients. Patients who went into
the Fontan operation with an elevated pulmonary
arterial pressure fared less well than their counter-
parts with lower pulmonary arterial pressures. Simi-
larly, the need for atrioventricular valve surgery at
the time of Fontan procedure conferred increased
risk, as did the absence of normal sinus rhythm.
Although the results following Fontan operations
have improved substantially, we should remember
that a signiﬁcant number of patients remain for whom
the surgery is not the ﬁnal intervention. The in-
vestigators report that 20% of Fontan survivors
required a pacemaker, 11% Fontan revision, and 5%
an intervention on the atrioventricular valve.
Although these numbers are likely inﬂated by those
who received a Fontan early in the Mayo experience,
they are useful as a reminder that the Fontan opera-
tion often is not the ﬁnal intervention for many
single-ventricle patients.
In addition to surgical reinterventions, there are
a signiﬁcant number of medical complications as-
sociated with long-term Fontan physiology. The
Fontan operation creates a circulation characterized
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1712by elevated central venous pressure and diminished
cardiac output. These alterations, although generally
well tolerated early in childhood, seem to be less well
tolerated over time, affecting organ systems outside
the heart. In recent years, numerous publications have
documented the near universal change to the archi-
tecture of the liver that occurs as a result of prolonged
exposure to the Fontan circulation (8,9). As inves-
tigators have focused on other organ systems, abnor-
malities have also been identiﬁed in bone and muscle
structure (10,11), endothelial reactivity (12), and the
characteristics of the immune system (13). In the cur-
rent paper, the authors report a 9% incidence of
protein-losing enteropathy, 41% incidence of late ar-
rhythmias, and, although data were available only for a
small subset, 21% incidence of liver cirrhosis in those
with available imaging or biopsy results. Theseﬁndings
are in line with other reports and reinforce the notion
that the Fontan operation does not create a normal
physiology. Instead, Fontan physiology can best be
thought of as aman-made form of chronic heart failure.
Within the spectrum of abnormalities related to
Fontan physiology, plastic bronchitis and protein-
losing enteropathy stand out as uniquely problem-
atic. Although the incidence reported in this paper and
others suggest that these affect a small minority of
patients, the lives of those who experience these
complications are substantially altered. The etiology
of plastic bronchitis and protein-losing enteropathy
are not entirely understood, but both are likely multi-
factorial, resulting from abnormal lymphatic dilation
in the setting of inﬂammation and perhaps a genetic
predisposition (14). Lymphatic interventions hold
some promise for the future, particularly for plastic
bronchitis, but this approach is not likely to be the ﬁnal
answer because the underlying physiology is generally
not altered (15). More work is needed to understand
who is most at risk and to continue to work toward
therapies successful at achieving long-term remission.Given the improvements in early and mid-term
outcomes described in this paper, focus has rightly
turned toward ﬁnding new ways to address the
morbidities associated with the Fontan circulation.
Novel therapies and approaches are needed to
improve the durability of the circulation to continue
improving on the basic physiological perturbations
created by the absence of a subpulmonary ventricle
and the reliance on passive pulmonary blood ﬂow.
Agents that target pulmonary vascular resistance
hold some intuitive promise. By decreasing pulmo-
nary vascular resistance, these agents can poten-
tially improve pre-load and therefore cardiac
output, while also lowering central venous pressure.
Although a number of short-term studies have
shown some potential promise, there has yet to be
a conclusive longer study demonstrating safety
and efﬁcacy for any single agent, and more work
is needed to truly understand whether this class
of medications might have a broad role in the
long-term care of patients after Fontan operation
(16,17).
Ultimately, the Fontan operation was a paradigm-
shifting advancement in the care of children born
with single-ventricle congenital heart disease.
Over the years, technical adjustments and improve-
ments in anesthesia and post-operative care have led
to substantial improvements in short- and long-term
survival as described in the current paper. However,
as a community, our work is not done. We need to
maintain our focus on ways to improve the efﬁciency
of this circulation to ensure that outcomes continue
to improve for future generations.
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